A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are encapsulated into recombinant adeno-associated virus (rAAV) capsids as ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

Recombinant DNA technologies developed in the early 1970s enabled scientists to isolate genes of interest and splice them into existing DNA structures. However, as late as the early 1980s, the ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

Berg was awarded one-half of the Nobel Prize in Chemistry in 1980 for his work with recombinant DNA technology. A series of rodent experiments showed that even with abundant food and water, personal ...

A phase II trial of an adenovirus/PSA vaccine for prostate cancer No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...